Full Text View
Tabular View
No Study Results Posted
Related Studies
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
This study has been completed.
Study NCT00035997   Information provided by Novartis
First Received: May 7, 2002   Last Updated: October 1, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Neoplasm Metastasis
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Zometa
Additional drug interventions recognized in this trial
Hormones
Zoledronic acid
More general drug interventions related to this trial
Bone Density Conservation Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services